advertisement
Tang X 18
Showing records 1 to 18 | Display all abstracts from Tang X104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Sun X
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Ye D; Xu Y
Journal of Pineal Research 2022; 73: e12828
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Liu Q
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Shi Y
Journal of Pineal Research 2022; 73: e12828
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Tang X
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Fan M
Journal of Pineal Research 2022; 73: e12828
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yao K; Li Y
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Lu P; Bai X
Journal of Pineal Research 2022; 73: e12828
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yang J
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Feng Y
Journal of Pineal Research 2022; 73: e12828
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Zhang M
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Hu C
Journal of Pineal Research 2022; 73: e12828
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Yuan H; Zheng Y
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Cui K
Journal of Pineal Research 2022; 73: e12828
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Li W
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Tang X; Liao J
Journal of Pineal Research 2022; 73: e12828
104851 Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
Peng H
BMC Ophthalmology 2022; 22: 332
105078 Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model
Huang W; Xu F; Liang X; Huang J
Journal of Pineal Research 2022; 73: e12828
